NASDAQ:AEON AEON Biopharma (AEON) Stock Price, News & Analysis → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free AEON Stock Alerts $5.07 +0.82 (+19.29%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$4.13▼$5.0750-Day Range$4.01▼$15.9552-Week Range$3.37▼$17.17Volume133,325 shsAverage Volume57,495 shsMarket Capitalization$191.60 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get AEON Biopharma alerts: Email Address AEON Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside255.0% Upside$18.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.18) to ($1.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.57 out of 5 starsMedical Sector662nd out of 916 stocksPharmaceutical Preparations Industry302nd out of 422 stocks 3.5 Analyst's Opinion Consensus RatingAEON Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAEON Biopharma has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for AEON. Previous Next 0.0 Dividend Strength Dividend YieldAEON Biopharma does not currently pay a dividend.Dividend GrowthAEON Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AEON. Previous Next 2.2 News and Social Media Coverage News SentimentAEON Biopharma has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.Search InterestOnly 2 people have searched for AEON on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added AEON Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AEON Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders20.00% of the stock of AEON Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.78% of the stock of AEON Biopharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AEON Biopharma are expected to grow in the coming year, from ($1.18) to ($1.16) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About AEON Biopharma Stock (NASDAQ:AEON)AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.Read More AEON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AEON Stock News HeadlinesApril 20, 2024 | americanbankingnews.comAEON Biopharma, Inc. to Post Q1 2024 Earnings of ($0.31) Per Share, HC Wainwright Forecasts (NASDAQ:AEON)April 19, 2024 | americanbankingnews.comHC Wainwright Weighs in on AEON Biopharma, Inc.'s Q1 2025 Earnings (NASDAQ:AEON)April 28, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.April 18, 2024 | markets.businessinsider.comAEON Biopharma: Buoyant Prospects Following FDA Alignment on Migraine StudiesApril 18, 2024 | americanbankingnews.comAEON Biopharma (NASDAQ:AEON) Receives "Buy" Rating from HC WainwrightMarch 30, 2024 | globenewswire.comCORRECTION -- AEON Biopharma Announces Redemption of Public WarrantsMarch 29, 2024 | globenewswire.comAEON Biopharma Announces Redemption of Public WarrantsMarch 29, 2024 | globenewswire.comAEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial ResultsApril 28, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.March 28, 2024 | seekingalpha.comLenz stock rallies 22% amid bullish note by Piper SandlerMarch 21, 2024 | investing.comAEON Biopharma secures $15 million in private placementMarch 19, 2024 | globenewswire.comAEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of MigraineMarch 19, 2024 | globenewswire.comAEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase AgreementsFebruary 26, 2024 | edition.cnn.comAEON Biopharma, Inc. Class AFebruary 6, 2024 | finanznachrichten.deDaewoong Pharmaceutical Co., Ltd.: Daewoong Pharmaceutical Announces 2023 Financial ResultsFebruary 1, 2024 | morningstar.comAeon Kyushu Co Ltd 2653January 31, 2024 | seekingalpha.comAEON.WS AEON Biopharma, Inc. WT EXP 072128January 18, 2024 | finance.yahoo.comAEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin ConferenceJanuary 10, 2024 | investing.comAeon Fantasy Co Ltd (4343)December 20, 2023 | morningstar.comXeris Biopharma Holdings Inc XERSDecember 12, 2023 | finance.yahoo.comAEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic MigraineNovember 15, 2023 | finance.yahoo.comAEON Biopharma Inc Reports Q3 2023 Financial Results Amid Clinical AdvancementsNovember 14, 2023 | msn.comAEON Biopharma, Inc. GAAP EPS of -$0.04November 13, 2023 | finance.yahoo.comAEON Biopharma Reports Third Quarter 2023 Financial ResultsSee More Headlines Receive AEON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AEON Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today4/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AEON Previous SymbolNASDAQ:AEON CUSIPN/A CIK1837607 Webwww.aeonbiopharma.com Phone754-220-9229FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$18.00 Low Stock Price Target$18.00 Potential Upside/Downside+255.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,630,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-46.82% Debt Debt-to-Equity RatioN/A Current Ratio0.48 Quick Ratio0.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.12) per share Price / Book-1.23Miscellaneous Outstanding Shares37,790,000Free Float30,231,000Market Cap$191.60 million OptionableNot Optionable Beta0.41 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Marc Forth (Age 52)President, CEO & Director Comp: $1.13MDr. Chad K. Oh M.D. (Age 65)Chief Medical Officer Comp: $587.4kMr. Peter A. Reynolds CPA (Age 66)Chief Financial Officer Mr. Alex Wilson (Age 37)Executive VP, Chief Legal Officer & Corporate Secretary Key CompetitorsProQR TherapeuticsNASDAQ:PRQRscPharmaceuticalsNASDAQ:SCPHGossamer BioNASDAQ:GOSSGreenwich LifeSciencesNASDAQ:GLSICapricor TherapeuticsNASDAQ:CAPRView All CompetitorsInsiders & InstitutionsFormidable Asset Management LLCSold 6,118 shares on 2/7/2024Ownership: 0.157%Crown Holdings Grou StrathspeySold 7,380,394 sharesTotal: $73.80 M ($10.00/share)View All Insider TransactionsView All Institutional Transactions AEON Stock Analysis - Frequently Asked Questions Should I buy or sell AEON Biopharma stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AEON Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AEON shares. View AEON analyst ratings or view top-rated stocks. What is AEON Biopharma's stock price target for 2024? 1 Wall Street analysts have issued twelve-month price objectives for AEON Biopharma's shares. Their AEON share price targets range from $18.00 to $18.00. On average, they anticipate the company's share price to reach $18.00 in the next twelve months. This suggests a possible upside of 255.0% from the stock's current price. View analysts price targets for AEON or view top-rated stocks among Wall Street analysts. How have AEON shares performed in 2024? AEON Biopharma's stock was trading at $7.20 at the beginning of 2024. Since then, AEON shares have decreased by 29.6% and is now trading at $5.07. View the best growth stocks for 2024 here. How were AEON Biopharma's earnings last quarter? AEON Biopharma, Inc. (NASDAQ:AEON) announced its earnings results on Friday, March, 29th. The company reported ($0.71) earnings per share for the quarter. When did AEON Biopharma IPO? AEON Biopharma (AEON) raised $75 million in an initial public offering (IPO) on Thursday, October 14th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. How do I buy shares of AEON Biopharma? Shares of AEON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AEON) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressThe World's First "$20 Trillion Drug?"Behind the MarketsMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AEON Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.